search
Back to results

Reduced Content of Gluten Diet on Patients With Irritable Bowel Syndrome (Pro.Ali.Fun.) (PROALIFUN)

Primary Purpose

Irritable Bowel Syndrome, Gluten Sensitivity

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Reduced gluten bread and Pasta compared o normal gluten bread and Pasta
Sponsored by
University of Bari
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Irritable Bowel Syndrome

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)Does not accept healthy volunteers

Inclusion Criteria:

  1. age above 18 years;
  2. having bowel symptoms (altered bowel habit, lower abdominal pain, bloating, or distention suggestive of IBS), as determined by Rome III criteria.
  3. Previous exclusion of CD and wheat allergy

Exclusion Criteria:

  1. previous GI malignancy and/or surgery;
  2. clinically significant cardiovascular, respiratory, endocrine, renal, hematologic or hepatic disease.
  3. other clinically significant medical condition; pregnancy or lactation; alcohol abuse; drug addiction; severe neurologic or psychiatric disorders; long-term use of corticosteroids or anti-inflammatory drugs
  4. participation in another clinical trial within 6 months before the onset of this trial.

    -

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    Reduced Gluten-Normal Gluten

    Normal Gluten-Reduced Gluten

    Arm Description

    Outcomes

    Primary Outcome Measures

    Change in Severity of IBS symptoms measured by Irritable Bowel Syndrome-Severity Score (IBS-SS)
    Change in IBS Severity Score (IBS-SS) between reduced gluten content diet and standard gluten content diet. Mild, moderate and severe cases were indicated by scores of 75 to 175, 175 to 300 and "300 respectively. Mild, moderate and severe cases are indicated by scores of 75 to 175, 175 to 300, and >300, respectively.
    Change of IBS severity measured by Visual analogue scale (VAS)
    Change of severity of IBS symptoms measured by Visual analogue scale (VAS) between reduced gluten content diet and standard gluten content diet. The 0-10 mm VAS scale (0 no pain, 10 worst possible pain) included a horizontal color gradient (green-red).

    Secondary Outcome Measures

    Change of Quality of life scores
    Irritable Bowel Syndrome Quality of Life (IBS-QoL) between reduced gluten content diet and standard gluten content diet.

    Full Information

    First Posted
    July 11, 2018
    Last Updated
    August 15, 2018
    Sponsor
    University of Bari
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03638544
    Brief Title
    Reduced Content of Gluten Diet on Patients With Irritable Bowel Syndrome (Pro.Ali.Fun.)
    Acronym
    PROALIFUN
    Official Title
    Effect of Wheat Bread and Pasta With Reduced Content of Gluten on Patients With Irritable Bowel Syndrome: Randomized Controlled Cross Over Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    January 1, 2014 (Actual)
    Primary Completion Date
    December 31, 2016 (Actual)
    Study Completion Date
    December 31, 2017 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Bari

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This study aim to manufacture bread and pasta with an reduced content of gluten and to assess the impact of reducing the daily intake of gluten by 50% in irritable bowel syndrome (IBS) patients. Fungal proteases and selected sourdough lactic acid bacteria will be used for making wheat bread and pasta with a reduced content of gluten (RG) (-50% of traditional products). From a technological point of view, the chemical, structural and sensory features of the RG products approached those of the bread and pasta made with normal level of gluten. The efficacy and safety of new products will be compared to traditional bread and pasta by using a double blind randomized, crossover-controlled trial in IBS patients with persistent gastrointestinal symptoms. Patients will follow two weeks of a GFD diet containing RG bread and pasta and two weeks of GFD diet containing Normal Gluten bread and pasta Symptoms severity will be assessed by Irritable Bowel Syndrome Severity Score (IBS-SS), Visual Analogue Scale (VAS), Hospital Anxiety and Depression Scale (HADS) and Irritable Bowel Syndrome Quality of Life (IBS-QoL).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Irritable Bowel Syndrome, Gluten Sensitivity

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Crossover Assignment
    Model Description
    Double blind placebo controlled Gluten Sensitivity
    Masking
    ParticipantCare ProviderInvestigator
    Allocation
    Randomized
    Enrollment
    20 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Reduced Gluten-Normal Gluten
    Arm Type
    Active Comparator
    Arm Title
    Normal Gluten-Reduced Gluten
    Arm Type
    Active Comparator
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Reduced gluten bread and Pasta compared o normal gluten bread and Pasta
    Intervention Description
    Pasta with low gluten (50% of the normal) content achieved by optimization of techological parameters such as dough yield, time of fermentation and concentration of fungal proteases The gluten reduction is obtained without any other intervention of wheat breeding or the endogenous proteolytic enzymes of flours.
    Primary Outcome Measure Information:
    Title
    Change in Severity of IBS symptoms measured by Irritable Bowel Syndrome-Severity Score (IBS-SS)
    Description
    Change in IBS Severity Score (IBS-SS) between reduced gluten content diet and standard gluten content diet. Mild, moderate and severe cases were indicated by scores of 75 to 175, 175 to 300 and "300 respectively. Mild, moderate and severe cases are indicated by scores of 75 to 175, 175 to 300, and >300, respectively.
    Time Frame
    two weeks of each different diet interspersed by one week of wash out. The questionnaire will be completed ones a week.
    Title
    Change of IBS severity measured by Visual analogue scale (VAS)
    Description
    Change of severity of IBS symptoms measured by Visual analogue scale (VAS) between reduced gluten content diet and standard gluten content diet. The 0-10 mm VAS scale (0 no pain, 10 worst possible pain) included a horizontal color gradient (green-red).
    Time Frame
    Two weeks of each different diet interspersed by one week of wash out. The scale will be completed ones a day.
    Secondary Outcome Measure Information:
    Title
    Change of Quality of life scores
    Description
    Irritable Bowel Syndrome Quality of Life (IBS-QoL) between reduced gluten content diet and standard gluten content diet.
    Time Frame
    two weeks of each different diet interspersed by one week of wash out. The scale will be completed ones a week.

    10. Eligibility

    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: age above 18 years; having bowel symptoms (altered bowel habit, lower abdominal pain, bloating, or distention suggestive of IBS), as determined by Rome III criteria. Previous exclusion of CD and wheat allergy Exclusion Criteria: previous GI malignancy and/or surgery; clinically significant cardiovascular, respiratory, endocrine, renal, hematologic or hepatic disease. other clinically significant medical condition; pregnancy or lactation; alcohol abuse; drug addiction; severe neurologic or psychiatric disorders; long-term use of corticosteroids or anti-inflammatory drugs participation in another clinical trial within 6 months before the onset of this trial. -

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Reduced Content of Gluten Diet on Patients With Irritable Bowel Syndrome (Pro.Ali.Fun.)

    We'll reach out to this number within 24 hrs